- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00093808
Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
Phase II Study of Capecitabine in Combination With Vinorelbine and Trastuzumab for the First- or Second-LineTreatment of HER2+ Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and vinorelbine, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor killing substances to them without harming normal cells. Giving capecitabine and vinorelbine together with trastuzumab may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving capecitabine and vinorelbine together with trastuzumab works in treating patients who have metastatic breast cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Determine the overall response rate in patients with HER2/neu-overexpressing metastatic breast cancer treated with first- or second-line therapy comprising capecitabine, vinorelbine, and trastuzumab (Herceptin^®).
Secondary
- Determine the time to disease progression, duration of response, and overall survival of patients treated with this regimen.
- Determine the safety profile of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral capecitabine twice daily on days 1-14, vinorelbine IV over 6-10 minutes on days 1 and 8, and trastuzumab (Herceptin^®) IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259-5499
- Mayo Clinic Scottsdale
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic - Jacksonville
-
-
Illinois
-
Aurora, Illinois, United States, 60504
- Rush-Copley Cancer Care Center
-
Bloomington, Illinois, United States, 61701
- St. Joseph Medical Center
-
Canton, Illinois, United States, 61520
- Graham Hospital
-
Carthage, Illinois, United States, 62321
- Memorial Hospital
-
Eureka, Illinois, United States, 61530
- Eureka Community Hospital
-
Galesburg, Illinois, United States, 61401
- Galesburg Cottage Hospital
-
Galesburg, Illinois, United States, 61401
- Galesburg Clinic, PC
-
Havana, Illinois, United States, 62644
- Mason District Hospital
-
Hopedale, Illinois, United States, 61747
- Hopedale Medical Complex
-
Joliet, Illinois, United States, 60435
- Joliet Oncology-Hematology Associates, Limited - West
-
Macomb, Illinois, United States, 61455
- Mcdonough District Hospital
-
Moline, Illinois, United States, 61265
-
Moline, Illinois, United States, 61265
- Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
-
Normal, Illinois, United States, 61761
- Bromenn Regional Medical Center
-
Normal, Illinois, United States, 61761
- Community Cancer Center
-
Ottawa, Illinois, United States, 61350
- Community Hospital of Ottawa
-
Ottawa, Illinois, United States, 61350
- Oncology Hematology Associates of Central Illinois, PC - Ottawa
-
Pekin, Illinois, United States, 61554
- Cancer Treatment Center at Pekin Hospital
-
Peoria, Illinois, United States, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, United States, 61614
- Proctor Hospital
-
Peoria, Illinois, United States, 61637
- OSF St. Francis Medical Center
-
Peoria, Illinois, United States, 61615
- CCOP - Illinois Oncology Research Association
-
Peoria, Illinois, United States, 61615
- Oncology Hematology Associates of Central Illinois, PC - Peoria
-
Peru, Illinois, United States, 61354
- Illinois Valley Community Hospital
-
Princeton, Illinois, United States, 61356
- Perry Memorial Hospital
-
Spring Valley, Illinois, United States, 61362
- St. Margaret's Hospital
-
Urbana, Illinois, United States, 61801
- Carle Cancer Center at Carle Foundation Hospital
-
Urbana, Illinois, United States, 61801
- CCOP - Carle Cancer Center
-
-
Indiana
-
Elkhart, Indiana, United States, 46515
- Elkhart General Hospital
-
Kokomo, Indiana, United States, 46904
- Howard Community Hospital
-
La Porte, Indiana, United States, 46350
- Center for Cancer Therapy at LaPorte Hospital and Health Services
-
Michigan City, Indiana, United States, 46360
- Saint Anthony Memorial Health Centers
-
South Bend, Indiana, United States, 46601
- Memorial Hospital of South Bend
-
South Bend, Indiana, United States, 46601
- CCOP - Northern Indiana CR Consortium
-
South Bend, Indiana, United States, 46617
- Saint Joseph Regional Medical Center
-
-
Iowa
-
Ames, Iowa, United States, 50010
- McFarland Clinic, PC
-
Bettendorf, Iowa, United States, 52722
-
Cedar Rapids, Iowa, United States, 52403
- Cedar Rapids Oncology Associates
-
Des Moines, Iowa, United States, 50309
- CCOP - Iowa Oncology Research Association
-
Des Moines, Iowa, United States, 50309
- John Stoddard Cancer Center at Iowa Methodist Medical Center
-
Des Moines, Iowa, United States, 50309
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center
-
Des Moines, Iowa, United States, 50314
- Medical Oncology and Hematology Associates at Mercy Cancer Center
-
Des Moines, Iowa, United States, 50314
- Mercy Cancer Center at Mercy Medical Center - Des Moines
-
Des Moines, Iowa, United States, 50316
- John Stoddard Cancer Center at Iowa Lutheran Hospital
-
Des Moines, Iowa, United States, 50307
- Mercy Capitol Hospital
-
Mason City, Iowa, United States, 50401
- Mercy Cancer Center at Mercy Medical Center - North Iowa
-
Ottumwa, Iowa, United States, 52501
- McCreery Cancer Center at Ottumwa Regional
-
Sioux City, Iowa, United States, 51101
- Siouxland Hematology-Oncology Associates, LLP
-
Sioux City, Iowa, United States, 51104
- St. Luke's Regional Medical Center
-
Sioux City, Iowa, United States, 51104
- Mercy Medical Center - Sioux City
-
-
Michigan
-
Adrian, Michigan, United States, 49221
- Hickman Cancer Center at Bixby Medical Center
-
Ann Arbor, Michigan, United States, 48106-0995
- Saint Joseph Mercy Cancer Center
-
Ann Arbor, Michigan, United States, 48106
- CCOP - Michigan Cancer Research Consortium
-
Dearborn, Michigan, United States, 48123-2500
- Oakwood Cancer Center at Oakwood Hospital and Medical Center
-
Escanaba, Michigan, United States, 49431
- Green Bay Oncology, Limited - Escanaba
-
Flint, Michigan, United States, 48503
- Hurley Medical Center
-
Flint, Michigan, United States, 48503
- Genesys Hurley Cancer Institute
-
Grosse Pointe Woods, Michigan, United States, 48236
- Van Elslander Cancer Center at St. John Hospital and Medical Center
-
Iron Mountain, Michigan, United States, 49801
- Dickinson County Healthcare System
-
Jackson, Michigan, United States, 49201
- Foote Memorial Hospital
-
Lambertville, Michigan, United States, 48144
- Haematology-Oncology Associates of Ohio and Michigan, PC
-
Lansing, Michigan, United States, 48912-1811
- Sparrow Regional Cancer Center
-
Livonia, Michigan, United States, 48154
- St. Mary Mercy Hospital
-
Monroe, Michigan, United States, 48162
- Community Cancer Center of Monroe
-
Monroe, Michigan, United States, 48162
- Mercy Memorial Hospital - Monroe
-
Pontiac, Michigan, United States, 48341-2985
- St. Joseph Mercy Oakland
-
Port Huron, Michigan, United States, 48060
- Mercy Regional Cancer Center at Mercy Hospital
-
Saginaw, Michigan, United States, 48601
- Seton Cancer Institute at Saint Mary's - Saginaw
-
St. Joseph, Michigan, United States, 49085
- Lakeland Regional Cancer Care Center - St. Joseph
-
Warren, Michigan, United States, 48093
- St. John Macomb Hospital
-
-
Minnesota
-
Alexandria, Minnesota, United States, 56308
-
Bemidji, Minnesota, United States, 56601
- MeritCare Bemidji
-
Burnsville, Minnesota, United States, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, United States, 55433
- Mercy and Unity Cancer Center at Mercy Hospital
-
Duluth, Minnesota, United States, 55805
- CCOP - Duluth
-
Duluth, Minnesota, United States, 55805-1983
- Duluth Clinic Cancer Center - Duluth
-
Duluth, Minnesota, United States, 55805
- Miller - Dwan Medical Center
-
Edina, Minnesota, United States, 55435
- Fairview Southdale Hospital
-
Fergus Falls, Minnesota, United States, 56537
-
Fridley, Minnesota, United States, 55432
- Mercy and Unity Cancer Center at Unity Hospital
-
Hutchinson, Minnesota, United States, 55350
- Hutchinson Area Health Care
-
Lichfield, Minnesota, United States, 55355
- Meeker County Memorial Hospital
-
Maplewood, Minnesota, United States, 55109
- Minnesota Oncology Hematology, PA - Maplewood
-
Maplewood, Minnesota, United States, 55109
- HealthEast Cancer Care at St. John's Hospital
-
Minneapolis, Minnesota, United States, 55407
- Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
-
Minneapolis, Minnesota, United States, 55415
- Hennepin County Medical Center - Minneapolis
-
Robbinsdale, Minnesota, United States, 55422-2900
- Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Cancer Center
-
Saint Cloud, Minnesota, United States, 56303
- CentraCare Clinic - River Campus
-
Saint Cloud, Minnesota, United States, 56303
- Coborn Cancer Center
-
Saint Louis Park, Minnesota, United States, 55416
- CCOP - Metro-Minnesota
-
Saint Louis Park, Minnesota, United States, 55416
- Park Nicollet Cancer Center
-
Saint Paul, Minnesota, United States, 55102
- United Hospital
-
Saint Paul, Minnesota, United States, 55102
- HealthEast Cancer Care at St. Joseph's Hospital
-
Shakopee, Minnesota, United States, 55379
- St. Francis Cancer Center at St. Francis Medical Center
-
St. Paul, Minnesota, United States, 55101
- Regions Hospital Cancer Care Center
-
Waconia, Minnesota, United States, 55387
- Ridgeview Medical Center
-
Woodbury, Minnesota, United States, 55125
- Minnesota Oncology Hematology, PA - Woodbury
-
Woodbury, Minnesota, United States, 55125
- HealthEast Cancer Care at Woodwinds Health Campus
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68510
- Cancer Resource Center - Lincoln
-
Omaha, Nebraska, United States, 68106
- CCOP - Missouri Valley Cancer Consortium
-
Omaha, Nebraska, United States, 68122
- Immanuel Medical Center
-
Omaha, Nebraska, United States, 68124
- Alegant Health Cancer Center at Bergan Mercy Medical Center
-
Omaha, Nebraska, United States, 68131-2197
- Creighton University Medical Center
-
-
North Dakota
-
Bismarck, North Dakota, United States, 58501
- Bismarck Cancer Center
-
Bismarck, North Dakota, United States, 58501
- Medcenter One Hospital Cancer Care Center
-
Bismarck, North Dakota, United States, 58501
- Mid Dakota Clinic, PC
-
Bismarck, North Dakota, United States, 58502
- St. Alexius Medical Center Cancer Center
-
Fargo, North Dakota, United States, 58122
- CCOP - MeritCare Hospital
-
Fargo, North Dakota, United States, 58122
- MeritCare Broadway
-
Grand Forks, North Dakota, United States, 58201
- Altru Cancer Center at Altru Hospital
-
-
Ohio
-
Bowling Green, Ohio, United States, 43402
- Wood County Oncology Center
-
Lima, Ohio, United States, 45804
- Lima Memorial Hospital
-
Maumee, Ohio, United States, 43537
- Northwest Ohio Oncology Center
-
Maumee, Ohio, United States, 43537
- St. Luke's Hospital
-
Oregon, Ohio, United States, 43616
- St. Charles Mercy Hospital
-
Oregon, Ohio, United States, 43616
- Toledo Clinic - Oregon
-
Sandusky, Ohio, United States, 44870
- Firelands Regional Medical Center
-
Sandusky, Ohio, United States, 44870
- North Coast Cancer Care, Incorporated
-
Sylvania, Ohio, United States, 43560
- Flower Hospital Cancer Center
-
Tiffin, Ohio, United States, 44883
- Mercy Hospital of Tiffin
-
Toledo, Ohio, United States, 43608
- St. Vincent Mercy Medical Center
-
Toledo, Ohio, United States, 43606
- Toledo Hospital
-
Toledo, Ohio, United States, 43614
- Medical University of Ohio Cancer Center
-
Toledo, Ohio, United States, 43617
- CCOP - Toledo Community Hospital
-
Toledo, Ohio, United States, 43623
- Toledo Clinic, Incorporated - Main Clinic
-
Wauseon, Ohio, United States, 43567
- Fulton County Health Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18105
- Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
-
Danville, Pennsylvania, United States, 17822-0001
- Geisinger Cancer Institute at Geisinger Health
-
Pittsburgh, Pennsylvania, United States, 15212
- Allegheny Cancer Center at Allegheny General Hospital
-
State College, Pennsylvania, United States, 16801
- Geisinger Medical Group - Scenery Park
-
Wilkes-Barre, Pennsylvania, United States, 18711
- Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57701
- Rapid City Regional Hospital
-
Sioux Falls, South Dakota, United States, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, United States, 57105
- Medical X-Ray Center, PC
-
Sioux Falls, South Dakota, United States, 57117-5039
- Sanford Cancer Center at Sanford USD Medical Center
-
-
Virginia
-
Fredericksburg, Virginia, United States, 22401
- Fredericksburg Oncology, Incorporated
-
-
Wisconsin
-
Green Bay, Wisconsin, United States, 54307-3508
- St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, United States, 54301-3526
- Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, United States, 54303
- Green Bay Oncology, Limited at St. Mary's Hospital
-
Green Bay, Wisconsin, United States, 54303
- St. Mary's Hospital Medical Center - Green Bay
-
La Crosse, Wisconsin, United States, 54601
- Franciscan Skemp Healthcare - La Crosse Campus
-
Marinette, Wisconsin, United States, 54143
- Bay Area Cancer Care Center at Bay Area Medical Center
-
Oconto Falls, Wisconsin, United States, 54154
- Green Bay Oncology, Limited - Oconto Falls
-
Sturgeon Bay, Wisconsin, United States, 54235
- Green Bay Oncology, Limited - Sturgeon Bay
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed invasive breast cancer
- Metastatic disease
HER2/neu-positive by immunohistochemistry (3+ by HercepTest^™ or equivalent) OR positive for amplification by fluorescent in situ hybridization
- Testing may be performed in the primary tumor or the metastatic site
- Received prior anthracycline or taxane as adjuvant therapy or for metastatic disease
Measurable disease
- At least one measurable lesion ≥ 2.0 cm by CT scan or MRI OR ≥ 1.0 cm by spiral CT scan
The following are considered non-measurable disease:
- Bone lesions
- Leptomeningeal disease
- Ascites
- Pleural/pericardial effusion
- Inflammatory breast disease
- Lymphangitis cutis/pulmonis
- Abdominal masses that are not confirmed and followed by imaging techniques
- Cystic lesions
- No bone metastases as the only evidence of metastasis
- Previously treated CNS metastases allowed provided disease has been stable for ≥ the past 3 months
Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS:
Age
- 18 and over
Sex
- Female or male
Performance status
- ECOG 0-2
Life expectancy
- At least 12 weeks
Hematopoietic
- Absolute neutrophil count ≥ 1,500/mm^3
- Hemoglobin ≥ 8.0 g/dL
- Platelet count ≥ 100,000/mm^3
- No known uncontrolled coagulopathy
Hepatic
- Bilirubin ≤ 3.0 times the upper limit of normal (ULN)
One of the following must be true:
- AST or ALT ≤ 5 times ULN AND alkaline phosphatase normal
- Alkaline phosphatase ≤ 5 times ULN AND AST or ALT normal
- Alkaline phosphatase ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN
- INR ≤ 1.5 times ULN
Renal
- Calcium ≤ 11.5 mg/dL
- Creatinine ≤ 1.5 times ULN
- Creatinine clearance ≥ 30 mL/min
Cardiovascular
- LVEF ≥ 50% by MUGA or echocardiogram
- No clinically significant (i.e., active) cardiac disease
- No congestive heart failure
- No symptomatic coronary artery disease
- No myocardial infarction within the past 12 months
- No cardiac arrhythmia not controlled with medication
Gastrointestinal
- Able to take oral medication
- No lack of physical integrity of the upper gastrointestinal tract
- No clinically significant malabsorption syndrome
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 30 days after study participation
- No history of allergy or hypersensitivity to study drugs, drug product excipients, including polysorbate 80, or chemically similar agents
- No prior unanticipated severe reaction to fluoropyrimidine therapy
- No know hypersensitivity to fluorouracil
- No known dihydropyrimidine dehydrogenase deficiency
- No history of uncontrolled seizures or CNS disorders
- No clinically significant psychiatric disability that would preclude giving informed consent or study compliance
- No other serious uncontrolled infection or disease
- No other malignancy within the past 5 years except cured basal cell skin cancer, carcinoma in situ of the cervix, or contralateral breast cancer
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Prior adjuvant trastuzumab (Herceptin^®) allowed as adjuvant or first-line therapy for metastatic disease
- No concurrent immunotherapy
Chemotherapy
- See Disease Characteristics
- No more than 1 prior chemotherapy regimen in the advanced or metastatic (non-adjuvant) setting
- No prior continuous (≥ 24 hours) fluorouracil infusion
- No prior capecitabine
- No prior oral fluoropyrimidines (e.g., eniluracil and fluorouracil, uracil and tegafur, S1, or emitefur)
Endocrine therapy
- At least 1 day since prior hormonal therapy
- No concurrent hormonal therapy
Radiotherapy
- More than 4 weeks since prior radiotherapy to the axial skeleton (i.e., skull, spinal column, sternum, or ribs)
- No concurrent radiotherapy
Surgery
- More than 4 weeks since prior major surgery
- No prior organ allografts requiring immunosuppressive therapy
Other
- More than 4 weeks since prior investigational drugs
- No concurrent sorivudine or its chemically related analogues (e.g., brivudine)
- No concurrent allopurinol, metronidazole, or cimetidine
- No other concurrent cytotoxic agents
- No other concurrent investigational drugs
- No other concurrent anticancer therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: capecitabine + vinorelbine + trastuzumab
Patients receive oral capecitabine twice daily on days 1-14, vinorelbine IV over 6-10 minutes on days 1 and 8, and trastuzumab (Herceptin^®) IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Confirmed Response Rate
Time Frame: Up to 5 years
|
A confirmed tumor response is defined to be either a Complete Response (CR) or Partial Response (PR) noted as the objective status on 2 consecutive evaluations at least 6 weeks apart.
All patients meeting the eligibility criteria who have signed a consent form and initiated study medication will be evaluable for response.
The proportion of confirmed tumor responses will be estimated by the number of tumor regressions that meet the RECIST criteria for a confirmed CR or PR divided by the total number of evaluable patients.
A 95% confidence interval for the true confirmed response rate will be calculated using the properties of the binomial distribution.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
|
Up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Progression (TTP)
Time Frame: Up to 5 years
|
Time to progression is defined as the time from registration to disease progression.
Patients who died without documentation of progression will be considered to have progressed on the date of their death.
If a patient starts treatment and fails to return for any evaluations, that patient will be censored for progression of disease at day one post-registration.
Otherwise, for patients that do not progress, censoring will occur at the last follow up date.
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as at least a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions or unequivocal progression of existing non-target lesions.
|
Up to 5 years
|
Duration of Response as Measured by RECIST Criteria
Time Frame: Up to 5 years
|
Duration of response is defined for all eligible patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a Complete Response (CR) or Partial Response (PR) to the date progression is documented.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions.
|
Up to 5 years
|
Overall Survival as Assessed by Time
Time Frame: Up to 5 years
|
Overall survival: The overall survival or survival time is defined as the time from registration to death due to any cause.
The distribution of overall survival will be estimated using the method of Kaplan-Meier method.
|
Up to 5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Winston Tan, MD, FACP, Mayo Clinic
Publications and helpful links
General Publications
- Tan WW, Allred JB, Salim M, Flynn P, Fishkin PA, Stella PJ, Wiesenfeld M, Bernath AM, Fitch TR, Perez EA. Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial. Clin Breast Cancer. 2012 Apr;12(2):81-6. doi: 10.1016/j.clbc.2012.01.001.
- Chumsri S, Sperinde J, Liu H, Gligorov J, Spano JP, Antoine M, Moreno Aspitia A, Tan W, Winslow J, Petropoulos CJ, Chenna A, Bates M, Weidler JM, Huang W, Dueck A, Perez EA. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clin Cancer Res. 2018 Jul 1;24(13):3053-3058. doi: 10.1158/1078-0432.CCR-17-1864. Epub 2018 Mar 12.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Trastuzumab
- Capecitabine
- Vinorelbine
Other Study ID Numbers
- NCCTG-N0337
- NCI-2012-02625 (Registry Identifier: CTRP (Clinical Trials Reporting System))
- CDR0000390344 (Registry Identifier: PDQ (Physician Data Query))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
Clinical Trials on capecitabine
-
Sun Yat-sen UniversityChengdu Biostar PharmaceuticalsNot yet recruitingBreast Neoplasms | Locally Advanced or Metastatic Breast CancerChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Hoffmann-La RocheCompletedBreast Cancer, Colorectal CancerNew Zealand, Australia, United Kingdom
-
Binghe XuHoffmann-La RocheUnknownSkin Diseases | Neoplasms by Site | Breast Neoplasms | Breast Diseases | Neoplasm MetastasisChina
-
Jules Bordet InstituteCompletedBreast Cancer | Elderly PatientsBelgium
-
Samsung Medical CenterCompletedAdvanced or Recurrent Esophageal Squamous Cell CarcinomaKorea, Republic of
-
Fudan UniversityCompletedMetastatic Breast CancerChina
-
Cancer Institute and Hospital, Chinese Academy...Hoffmann-La RocheUnknownCarcinoma, Invasive Ductal, BreastChina
-
The First Affiliated Hospital of Zhengzhou UniversityRecruiting
-
Jiangxi Provincial Cancer HospitalRecruitingNasopharyngeal Carcinoma | Maintenance Therapy | High-Risk CancerChina